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ABSTRACT--We have assessed the effect of two ether glycerol lipids, 77-6 ((2S, 3R)-4-
(Tetradecyloxy)-2-amino-1,3-butanediol) and 56-5 ((S)-2-Amino-3-O-hexadecyl-1-propanol), 
which are substrates for sphingosine kinases, on inflammatory responses. Treatment of 
differentiated U937 macrophage-like cells with 77-6 but not 56-5 enhanced IL-1E release; 
either alone or in the presence of LPS.  The stimulatory effect of sphingosine or 77-6 on LPS-
stimulated IL-1E release was reduced by pretreatment of cells with the caspase-1 inhibitor, 
Ac-YVAD-CHO, thereby indicating a role for the inflammasome.  The enhancement of LPS-
stimulated IL-1E release in response to sphingosine, but not 77-6, was reduced by 
pretreatment of cells with the cathepsin B inhibitor, CA074Me, indicating a role for 
lysosomal destabilization in the effect of sphingosine.  Administration of 56-5 to mice 
increased disease progression in an experimental autoimmune encephalomyelitis model and 
this was associated with a considerable increase in the infiltration of CD4+ T-cells, CD11b+ 
monocytes and F4/80+ macrophages in the spinal cord.  56-5 and 77-6 were without effect on 
the degradation of myc-tagged sphingosine 1-phosphate 1
 
receptor in CCL39 cells.  
Therefore, the effect of 56-5 on EAE disease progression is likely to be independent of the 
inflammasome or the sphingosine 1-phosphate 1
 
receptor.  However, 56-5 is chemically 
similar to platelet activating factor and the exacerbation of EAE disease progression might be 
linked to platelet activating factor receptor signaling. 
 
Introduction 
Innate immunity to pathogens uses pathogen-associated molecular patterns (PAMPs) to 
increase IL-1E and IL-18 release from inflammatory cells (Schroder & Tschopp, 2010).  
Lipopolysaccharide (LPS) is an example of a PAMP that can bind to Toll-Like Receptors 
(TLR) to initiate innate immune responses (Takeuchi & Akira, 2010).  In addition, during 
sterile inflammation, danger-associated molecular patterns (DAMPs) can be released from 
dead cells to promote innate immune responses via TLR-dependent pathways (Chen & 
Nunez, 2010). The NLRP (NOD-like receptor family, pyrin domain containing) 
inflammasome senses DAMPs, resulting in the binding of apoptosis-associated speck-like 
protein containing a caspase recruitment domain (ASC) to the inflammasome. This, in turn, 
promotes assembly and activation of caspase-1, which cleaves pro-IL-1E to produce bioactive 
IL-1E which is then released from cells (Brough & Rothwell, 2007). DAMPs might also be 
released from the damage to lysosomal membranes, which is regulated by lysosomal 
proteases, such as cathepsin B (Hornung & Latz, 2010). Recently, Luheshi et al. (2012) 
demonstrated that sphingosine and the sphingosine analogue, FTY720, promote the NLRP3-
dependent release of IL-1E from LPS-stimulated macrophages, as this was not evident in 
macrophages derived from Nlrp3-/- mice.  The effect of sphingosine on IL-1E release involves 
the protein phosphatase 2A and/or protein phosphatase 1 (PP2A/PP1). Thus, the PP2A/PP1 
inhibitors okadaic acid and calyculin A prevented sphingosine-induced IL-1E release from 
macrophages (Luheshi et al. 2012).  Moreover, sphingosine-induced IL-1E release was 
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unaffected by the cathepsin B inhibitor, CA074Me, or the pan-cysteine protease inhibitor, 
E64 (Luheshi et al. 2012).  The possibility that the effect of sphingosine on NLRP3-
dependent release of IL-1Eis mediated through metabolites of sphingosine was excluded 
based on the finding that ceramide, which is formed by acylation of sphingosine (catalysed 
by ceramidase and/or ceramide synthase) had no effect on IL-1E release.  Moreover, much 
higher concentrations of sphingosine 1-phosphate (compared with sphingosine), which is 
produced by phosphorylation of sphingosine by the action of sphingosine kinase (two 
isoforms termed SK1 and SK2), were required in order to stimulate IL-1Erelease (Luheshi et 
al. 2012).  These findings can possibly be explained by evidence showing that sphingosine 
potently binds to the acidic leucine rich nuclear phosphoprotein-32A (ANP32A) to activate 
PP2A (Habrukowich et al. 2010), and that this might also underlie the ability of sphingosine 
to inhibit cell growth and induce apoptosis of mammalian cells (Ohta et al. 1995; Nava et al. 
2000) and to reduce tumour growth in vivo (Kohno et al. 2006). 
 
Multiple sclerosis is an autoimmune inflammatory demyelinating disease involving reactive 
T-lymphocytes. There is also a strong prognostic relationship between IL-1E levels and 
disease progression and mutation of the Nlrp3 gene is associated with MS-like lesions 
(Compeyrot-Lacassagne et al. 2009; Dodé, et al. 2002).   In addition, mice lacking the gene 
encoding NLRP3 (Nlrp3-/-) develop significantly milder symptoms in an experimental 
autoimmune encephalomyelitis (EAE) model and exhibit a reduction in IFNJ- and IL-17-
expressing TH cells in peripheral lymphoid tissues and the spinal cord (Gris et al. 2010; 
Inoue et al. 2012). IL-1E also induces activation of microglial cells, which stimulate T-
lymphocytes with self-antigen during EAE development.  In addition, IL-1 receptor deficient 
mice develop milder EAE and reduced TH17 cells (Sutton et al. 2006).  There is also a 
relationship between multiple sclerosis, NLRP3 inflammasome and the sphingosine 
analogue, FTY720.  Indeed, FTY720 has been shown to activate PP2A, to stimulate IL-E 
release via an NLRP3-dependent mechanism in macrophages (Luheshi et al. 2012) and to 
modulate the immune response by preventing egress of T-lymphocytes from lymph nodes 
(Hla & Brinkmann, 2011).  FTY720 is licenced for oral treatment of relapsing multiple 
sclerosis under the trade name GilenyaTM. FTY720 is a prodrug, which is phosphorylated by 
SK2 and is a functional antagonist of sphingosine 1-phosphate receptor 1 (S1P1), causing this 
receptor to be degraded by the proteasome and removed from T-lymphocytes (Hla & 
Brinkmann, 2011).  Since T-lymphocytes use an S1P gradient to egress from lymph nodes, 
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FTY720 is able to prevent this by creating S1P1 null T-lymphocytes that do not respond to the 
S1P gradient.  This traps the T-lymphocytes in lymph nodes, thereby preventing their action 
on the CNS in multiple sclerosis.   
 
In the current study, we have assessed whether ether glycerol lipids can affect 
inflammasome-dependent IL-1E release from macrophages and modify disease progression 
in the EAE model.  The rationale for this was three-fold.  First, there is structural similarity of 
the ether glycerol lipids with sphingosine and therefore these molecules might act in a similar 
manner as sphingosine to modulate inflammasome-dependent IL-1Erelease.  Second, if 
modulation of inflammasome-dependent IL-1Erelease is evident, then these ether glycerol 
lipids might serve as a starting point for the synthesis of potent inhibitors of the 
inflammasome that can be used therapeutically to abrogate inflammatory diseases.  
Alternatively, the synthesis of potent inflammasome activators could be used promote innate 
immunity against invading pathogens.  Third, previous studies using 1-O-hexadecyl-2-
desoxy-2-amino-sn-glycerol (which is 56-5) have demonstrated its phosphorylation by SK1 
(Km = 3.8 PM, compared with Km = 15.7PM for sphingosine (sphing-4-enine) (Gijsbers et al. 
2002). Indeed, we show here that ether glycerol lipids are substrates for SK1 and SK2, and 
that 77-6 is a powerful stimulator of IL-1E release from macrophages.  However, 56-5 which 
fails to stimulate IL-1E release in U937 macrophage-like cells, increases disease progression 
in the EAE model.  This action of 56-5 might be related to its chemical similarity with 
platelet activating factor, which also has a role in multiple sclerosis (Kihara et al. 2005).  
 
Results and Discussion 
77-6 and 56-5 are substrates for both SK1 and SK2--We assessed whether several ether 
glycerol lipids (56-2, 56-3, 56-4, 56-5, 77-5 and 77-6; Fig. 1) and a sphingosine analogue (67-
622, Fig. 1) inhibit SK1 and SK2 activity and/or function as substrates for these enzymes 
(Table 1). The replacement of the azide group in 56-4; a compound which inhibited SK2 
activity, with an -NH2 group produced compound 56-5 ((S)-2-Amino-3-O-hexadecyl-1-
propanol or 1-O-hexadecyl-2-desoxy-2-amino-sn-glycerol), which was a substrate for SK2 
(Table 1). 56-5 was also a weak substrate for SK1, being ~ 5 times less effective than for SK2 
(Table 1).  Similarly, replacement of the azide in 77-5 with an –NH2 group produced 
compound 77-6 ((2S, 3R)-4-(Tetradecyloxy)-2-amino-1,3-butanediol), which was a substrate 
for SK2; this being ~ 3 times as effective compared with 56-5 (Table 1).  Therefore, reduction 
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in the alkyl chain length from C16 to C14 and introduction of the 3-hydroxyl group, enhanced 
substrate utilization by SK2.  Indeed, the 3-hydroxyl group of the naturally occurring 
substrate of SK2, sphingosine, might H-bond with D308 to orientate the 1-hydroxyl group for 
phosphorylation by the enzyme. 77-6 was also a preferred substrate for SK1 compared with 
56-5.  56-5 and 77-6 bear chemical resemblance with sphingoid bases and this might therefore 
provide explanation for why these molecules can function as substrates for both SK1 and 
SK2. Indeed, the effect of carbon alkyl chain length on the efficiency of phosphorylation 
suggests an optimal fit in the catalytic site of both SK1 and SK2 in terms of the positioning 
the –OH group in the sphingosine binding pocket close to the deprotonating base to enable 
efficient phosphorylation.  In contrast, the sphingosine analogue, 67-622 was a selective 
inhibitor of SK1 with no inhibitor activity against SK2 (Table 1).  67-622 was not a substrate 
for SK1 or SK2 (Table 1).   
. 
Effect of 77-6 and 56-5 on IL-1E release--Others have shown that sphingosine stimulates IL-
1E release from macrophages via activation of the NLRP3 inflammasome (Luheshi et al. 
2012).  Therefore, given the chemical similarity with sphingosine, we investigated the effect 
of 56-5 and 77-6 on IL-1E release from macrophages.  We show here that treatment of 
differentiated (macrophage-like) U937 cells with 77-6 (10 PM) increased basal and LPS-
stimulated IL-1E release in differentiated U937 cells (Fig. 2A, B).   Similarly, treatment of 
differentiated U937 cells with sphingosine enhanced LPS-stimulated IL-1E release (Fig. 3).  
In contrast, 56-5 (10 PM) was ineffective in stimulating IL-1E release from these cells; either 
alone or in the presence of LPS (Fig. 2A, B).  Thus, the presence of the 3–OH group and/or 
C14 alkyl chain length (2 carbons shorter than in 56-5) in 77-6 is required to stimulate IL-1E 
release from macrophages suggesting some structural-activity relationship with respect to the 
modulation of inflammasome activity. 
 
In order to exclude the possibility that potential metabolites of sphingosine are responsible for 
its effects on IL-1E release, we tested S1P, which is formed by the action of sphingosine 
kinase on sphingosine.  We also tested the effect of short chain ceramides.  S1P and short 
chain ceramides and the SK2 selective inhibitor, (R)-FTY720 methylether (ROMe) (Lim et al. 
2011b) had no effect on LPS-stimulated IL-1E release (Fig. 4). Similarly, the SK1/2 inhibitor, 
SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole) failed to modulate LPS-stimulated IL-
1Erelease (data not shown).  Taken together, these results suggest that the effect of 77-6 (Fig. 
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2) is not via modulation of the sphingolipid rheostat (e.g. inter-conversion of ceramide, 
sphingosine and S1P).  Neither sphingosine, 56-5 nor 77-6 affected basal or LPS-stimulated 
TNFDrelease (data not shown), suggesting that the ability of 77-6 to increase IL-1Erelease is 
regulated by a distinct mechanism (e.g. inflammasome) from that regulating TNFD 
expression.  
 
The effect of sphingosine or 77-6 on LPS-stimulated IL-1E release was reduced by 
pretreatment of cells with the caspase-1 inhibitor, Ac-YVAD-CHO (Fig. 5), thereby 
indicating a role for the inflammasome.  LPS-stimulated IL-1E release in response to 
sphingosine, but not 77-6, was reduced by pretreatment of cells with the cathepsin B inhibitor, 
CA074Me (Fig. 6), indicating a role for lysosomal destabilization in the effect of sphingosine, 
but not 77-6.  Treatment of cells with the PP2A inhibitor, okadaic acid (0.5 PM) had no effect 
on the enhancement of LPS-stimulated IL-1E release by 77-6 or sphingosine (Fig. 7).  Higher 
concentrations of okadaic acid (2 PM) actually enhanced LPS-stimulated IL-1Eformation 
(data not shown).  These findings are different from those reported for primary macrophages, 
where okadaic acid reduced the effect of sphingosine on IL-1E release and CA074Me had no 
effect.  There is a major difference in the response of U937 macrophage like cells and primary 
macrophages, as in the latter case, LPS alone has no effect on IL-1E release (Luheshi et al. 
2012), while in U937 macrophage like cells, LPS alone is able to stimulate IL-1E release.  
These findings suggest that the mechanisms of LPS-stimulated IL-1E release are somewhat 
different in the two cell systems.  Therefore, it is reasonable to conclude that the DAMP-
mediated effect of sphingosine could also involve different mechanisms of inflammasome 
modulation in the two cellular systems.  For instance, different family members of NLRP 
inflammasome might be involved in the two cell types.  The effect of sphingosine, but not 77-
6, on LPS stimulation of IL-1E release was also reduced by the cyclic AMP elevating agent, 
forskolin (Fig. 8), thereby indicating along with the differential effect of cathepsin B inhibitor, 
that sphingosine and 77-6 use different mechanisms involving the inflammasome to potentiate 
LPS-stimulated IL-1E release from macrophages. 
 
Effect of 56-5 and 77-6 on disease progression in EAE--Since the inflammasome is linked 
with multiple sclerosis, we tested the effect of 56-5 and 77-6 on disease progression in EAE, 
an animal model of multiple sclerosis.  In this regard, 56-5 increased disease progression 
(clinical score) with an earlier onset of symptoms that were more severe (Fig. 9A) in the EAE 
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model and induced a considerable increase in infiltration in CD4+ T-cells, CD11b+ monocytes 
and F4/80+ macrophages in the spinal cord (Fig, 9B).  In contrast, 77-6 was without effect on 
disease progression (Fig. 9A B).  FTY720, used as a positive control, completely ablated 
disease progression (clinical score) in the EAE model (Fig. 9A).  These findings demonstrate 
the opposite structural-activity relationship when compared to the modulation of IL-1E release 
and suggest that the targets for 77-6 and 56-5 are different in the two experimental systems.  
The amino ether lipid 56-5 is an intermediate in the chemical synthesis of an amide analogue 
of PAF (1-O-alkyl-2-acetyl-sn-glycerol-3-phosphocholine) (Chandrakumar & Hadju, 1982) 
and bears some chemical similarity to PAF, which is also involved in disease progression in 
EAE.  Indeed, PAF levels and PAF receptor mRNA expression in the spinal cord are 
correlated with the EAE disease progression.  Moreover, PAF receptor knockout mice exhibit 
a lower incidence and less severe symptoms in the chronic phase of EAE compared with WT 
mice (Kihara et al. 2005). In addition, macrophages from PAF receptor knockout mice exhibit 
enhanced phagocytic activity and TNF-D production.  Therefore, the ability of 56-5 to 
enhance disease progression in the EAE model might be related to its potential activity in 
modulating PAF receptor signaling. This possibility will be tested by further experimentation 
in the future.   
 
Effect of FTY720, 56-5 and 77-6 on S1P1 receptor internalization--Since FTY720, when 
converted by SK2 to FTY720-phosphate, is a functional antagonist of the S1P1 receptor and 
this underlies a major part of its action in alleviating MS disease progression, we assessed the 
effect of 56-5 and 77-6 (both SK2 substrates) on S1P1 receptor degradation in CCL39 cells 
(an expression system for analyzing S1P1 receptor modifying agents) that were engineered to 
stably over-express S1P1. Unlike FTY720, which significantly reduced EAE severity and 
S1P1 levels in CCL39 cells, 56-5 and 77-6 were without effect on the degradation of this 
receptor (Fig. 10), and also failed to stabilize the receptor as neither 56-5 nor 77-6 stimulated 
increased expression of S1P1.  Therefore, it is unlikely that the effects of 56-5 on EAE 
progression involve modulation of the S1P1 receptor or T-lymphocyte trafficking from lymph 
nodes via this mechanism (although this would need to be tested in T-cells themselves), 
despite increasing CD4+ infiltration into the spinal cord. 
 
Conclusion 
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The ability of 56-5 to increase disease progression in the EAE model is not likely to be linked 
with the inflammasome based on the finding that 56-5 failed to increase IL-1E release from 
differentiated U937 cells; either alone or in the presence of LPS.  Moreover, a significant role 
for inflammasome in the action of 77-6 is unlikely as although this compound does stimulate 
IL-1E release from macrophages, it had no significant effect on disease progression in the 
EAE model. Therefore, we have demonstrated a structural activity relationship in terms of 
regulation of the inflammasome and EAE disease progression by ether glycerol lipids, albeit 
that these relationships are opposed.   The concentration of 77-6 used to modulate IL-1E 
release is moderate (PM), and future development is required in order to increase potency.  If 
this can be achieved, then consideration could be given for the use of glycerol lipids, possibly 
as potential PAF antagonists, for use in multiple sclerosis or inhibitors of inflammasome 
activity.  Clearly this would involve synthesis of compounds where stimulatory activity is 
switched to inhibitory activity by chemical design.  The objective would be the development 
of antagonists that block, for instance, sphingosine-dependent activation of IL-1E release in 
inflammatory disease.  Alternatively, activators of IL-1E release could be exploited to 
promote innate immunity against pathogens. 
 
Materials and Methods 
HEK 293, U937 and CCL39 Cell Culture--HEK 293 cells stably over-expressing GFP-SK1 
(30-fold increase in SK1 activity vs. vector-transfected cells) were cultured in DMEM 
supplemented with 10% European fetal calf serum, 100 U/mL penicillin, 100 Pg/mL 
streptomycin, 1% non-essential amino acids, and 0.8% geneticin at 37 °C in 5% CO2. U937 
cells (ATCC) were maintained in RPMI medium (Life Technologies), supplemented with 
10% (v/v) foetal bovine serum (Seralabs), 1U /ml penicillin, 1 mg/ml streptomycin and 2 mM 
L-glutamine (Life Technologies; complete RPMI).  U937 cells were differentiated using PMA 
as previously described by others (Shepherd et al. 2004; Twomey et al. 1993). Briefly, cells 
were plated at 1 × 106 cells/ml in complete RPMI supplemented with 4nM PMA. Medium 
was replenished after two days. After 4 days, the cells were then cultured in complete RPMI 
in the absence of PMA for a further 24 hours.  U937 cells were stimulated with 1 µg/ml LPS 
(Sigma) for 2 hours, after which compounds at indicated concentrations were added for 1 
hour. Supernatants were collected and assayed for IL-ȕ SURWHLQ H[SUHVVLRQ E\ (/,6$
according to the manufacturer’s instructions (R&D Systems).  CCL39 cells that were stably 
transfected with myc-tagged S1P1 (Rutherford et al., 2013) were maintained in DMEM with 
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GlutaMAXTM supplemented with 10% (v/v) foetal bovine serum, 100(?XQLWVPOSHQLFLOOLQDQG
100(?ȝg/ml streptomycin at 37(?&LQDKXPLGLILHGDWPRVSKHUHFRQWDLQLQJYY&22.  Cells 
grown to confluence on 12 well plates were quiesced for 24 hours prior to treatment with 
FTY720 (100 nM) or 77-6 (10 PM) or 56-5 (10 PM) for 24 hours.  Cell lysates were analysed 
by SDS-PAGE and western blotted for myc-tagged S1P1 (# sc-40, Santa Cruz) and re-probed 
for ERK-2 (# 610104, Transduction Laboratories) to ensure equal protein loading. It is 
standard practice to differentiate U937 myeloid to macrophages to study inflammatory 
responses e.g. IL-1E release.  HEK293 cells and CCL39 cells are used as standard for over-
expression of recombinant proteins (in this case SK1 or S1P1) in order to allow testing of 
compounds for target engagement. 
 
Western Blotting--Upon treatment, cells were lysed in sample buffer (62.5 mM Tris-HCl (pH 
6.7), 0.5 M sodium pyrophosphate, 1.25 mM EDTA, 1.25% (w/v) sodium dodecyl sulphate, 
0.06% (w/v) bromophenol blue, 12.5% (v/v) glycerol (all from Sigma) and 50 mM 
dithiothreitol (Enzo)). Proteins were separated on a 10% (v/v) acrylamide/bisacrylamide gel, 
and transferred to a nitrocellulose Hybond membrane (GE Healthcare). Membranes were 
blocked in 5% (w/v) BSA (Fisher) in TBST buffer (20mM Tris-HCl (pH 7.5), 48mM NaCl, 
0.1% (v/v) Tween20) for 1 hour at room temperature prior to incubation with primary antibody 
(diluted in blocking buffer) overnight at 4ºC. Following three washes in TBST, membranes 
were incubated with secondary antibody (Sigma; diluted in blocking buffer) for 1 hour at room 
temperature. Immunoreactive protein bands were visualized using ECL. 
 
Sphingosine Kinase Activity Assays--To assess the compounds as potential inhibitors of SK1 
and SK2, enzyme activity was assayed at the Km values for sphingosine (SK1, 3 PM; SK2, 10 
PM).  This corresponds to 50% substrate saturation, thereby enabling a qualitative estimation of 
selectivity by comparing the % modulation of each kinase using a fixed concentration of 
compound (50 PM).   In order to measure SK2 activity, Sph was complexed with fatty acid free 
bovine serum albumin (final concentration, 0.2 mg/mL) in buffer A containing 20 mM Tris (pH 
7.4), 1 mM EDTA, 1 mM Na3VO4, 40 mM E-glycerophosphate, 1 mM NaF, 0.007% (v/v) E-
mercaptoethanol, 20% (v/v) glycerol, 10 ȝg/ml aprotinin, 10 ȝg/mL soybean trypsin inhibitor, 1 
mM PMSF, 0.5 mM 4-deoxypyridoxine, and 400 mM KCl. SK2 assays were performed using 
37 ng of purified SK2 and incubating the assay for 30 min at 30 °C in the presence of 10 µM 
Sph, 250 µM [J-32P]-ATP (Perkin Elmer) in 10 mM MgCl2, and varying concentrations of the 
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inhibitors dissolved in DMSO or control (5% v/v DMSO). To measure SK1 activity, Sph was 
solubilized in Triton X-100 (final concentration, 0.063% w/v) and combined with buffer A 
without KCl. 30 Pg of recombinant SK1 was incubated for 30 min at 30 °C, in the presence of 
3 µM Sph, 250 µM [J-32P]-ATP in 10 mM MgCl2 with or without inhibitor dissolved in DMSO 
or control (5% v/v DMSO). Both assay reactions were termLQDWHGE\WKHDGGLWLRQRIȝO of 
1-butanol. After 1 ml of 2 M KCl was added, with mixing, two phases were formed. The lower 
(aqueous) phase, which contains unreacted [J-32P]-ATP, was removed and discarded. The 
organic phase containing [32P]-S1P was extracted by washing twice with 2 M KCl (1 ml each 
time) before quantification by Cerenkov counting. To evaluate the test compounds as putative 
substrates of SK1 and SK2, the assay was conducted in the presence of 50 PM of the test 
compound (but in the absence of Sph) and radioactivity in the 1-butanol phase was quantified. 
 
Mice--C57BL/6 mice were purchased from Harlan (UK) and maintained at the Biological 
Procedure Unit, University of Strathclyde. All experiments were performed under the guidelines 
of the UK Home Office Animals (Scientific Procedures) Act 1986. Female mice at the age of 7–
12 weeks were used in all experiments. 
 
EAE Induction and Clinical Evaluation--Mice were immunized subcutaneously on the back 
with 100 Pg of MOG35-55 peptide (Sigma Genosys) in 50 µl of PBS emulsified with an equal 
volume of CFA (total 125 Pg of Mycobacterium tuberculosis, strain H37RA, Difco, Detroit MI) 
as before (Jiang et al., 2012).  Each mouse also received intraperitoneally (i.p.) 100 ng/200 Pl of 
PTX (Sigma, UK) in PBS on days 0 and 2 post immunization. EAE was scored according to a 0 
- 5 scale as follows: 0, no clinical sign; 1, complete loss of tail tone; 2, hind limb weakness; 3, 
hind limb paralysis; 4, forelimb involvement; 5, moribund. 
 
 Preparation of Compounds, Dosage and Route of Administration--All compounds were 
dissolved in a vehicle solution of 20% cyclodextrin in phosphate buffered saline. FTY720 
(Cambridge Bioscience, UK) was prepared as 0.05 mg/ml stock. The dosage given to the mice 
was 0.4 mg/kg.  Compound 56-5 was prepared as 0.25 mg/ml stock. The dosage given was 2 
mg/kg (the approximate in vivo concentration is 6.3 PM assuming 100% bioavailability). 
Compound 77-6 was prepared as 1.0 mg/ml stock. The dosage given was 8 mg/kg (the 
approximate in vivo concentration is 25 PM assuming 100% bioavailability). The compounds 
were all administered i.p. daily from day 0 of MOG immunization at the above doses. The EAE 
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control group received i.p. injection daily of the 20% cyclodextrin vehicle.  
 
Immunohistochemical Staining--Mice were euthanized in CO2 chamber and their spinal cords 
were flushed out with PBS by hydrostatic pressure using a syringe. Tissues were immediately 
frozen in OCT and 6-8Pm thick sections were stained with specific primary antibodies for 
CD4, CD11b and F4/80 (all from e-Bioscience) overnight. Sections were then washed and 
incubated with biotinylated secondary antibody (Vector Laboratories) and streptavidin-HRP 
(eBioscience) before being detected with ImmPACT AMEC red peroxidise substrate (Vector 
Laboratories). Sections were then washed in distilled water and counterstained with 
haematoxylin. Isotypes with matching IgG were used as negative control and showed no 
staining in all tissues.  
 
 
Chemical Synthesis 
3-O-Hexadecyl-sn-glycerol (van Boeckel et al. 1982). To a suspension of 0.80 g (20.0 mmol) 
of sodium hydride (60% in white oil, washed with dry hexane twice) in 50 mL of dry THF was 
added 1.33 g (10.0 mmol) of 1,2-O-isopropylidene-sn-glycerol at 0 °C.  After the evolution of 
hydrogen stopped, 3.1 mL (10.1 mmol) of n-hexadecyl bromide and 0.33 g (1.0 mmol) of n-
Bu4NBr were added.  The mixture was stirred for 24 h at room temperature, and then the 
reaction was quenched with 10 mL of methanol.  The solvent was removed under reduced 
pressure and the residue was diluted with 100 mL of ether, and then washed with water.  The 
organic layer was concentrated under reduced pressure.  The residue was treated with 0.19 g 
(1.0 mmol) of p-toluenesulfonic acid (p-TsOH) in 50 mL of MeOH, and then was stirred 
overnight.  Removal of the solvent gave a residue that was purified by column chromatography 
on silica gel (elution with hexane/EtOAc 1:1), affording 2.66 g (84%) of 3-O-hexadecyl-sn-
glycerol as a white solid; mp 64.0-67.0 °C [63.0-64.0 °C]; [D]25D +2.69° (c 5.0, THF) [[D]25D 
+2.69° (c 3.5, THF)]; 1H NMR (CDCl3) G 0.88 (t, 3H, J = 6.6 Hz), 1.26 (s, 26H), 1.50-1.60 (m, 
2H), 2.55 (s, 2H), 3.44-3.49 (m, 4H), 3.50 (dd, 1H, J = 5.3, 11.3 Hz), 3.68 (dd, 1H, J = 5.3, 
18.4 Hz), 3.80-3.90 (m, 1H); 13C NMR G 14.1, 22.7, 26.1, 29.3, 29.4, 29.6, 29.6, 29.6, 29.7, 
31.9, 64.2, 70.5, 71.8, 72.5. 
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(S)-3-Hexadecyloxy-2-methoxy-1-propylamine (56-3) (Tsuri et al. 1992). 1-O-Hexadecyl-2-
O-methyl-sn-glycerol was synthesized by O-methylation of 1-O-hexadecyl-3-O-(4-
methoxyphenyl)-sn-glycerol as described previously (Byun et al. 1994). The azido group was 
introduced into the sn-3 position of 1-O-hexadecyl-2-O-methyl-sn-glycerol by using tosyl 
chloride followed by sodium azide as described previously. The azide group was reduced by 
hydrogenation of 56-2 (54 mg, 0.15 mmol) with Pd/C (5 mg) in methanol (20 mL), with 
stirring overnight. After Pd/C was removed by passing the mixture through a pad of Celite, the 
filtrate was concentrated under reduced pressure to give 50 mg of the target amino alcohol, 56-
3.   
 
 
 
(S)-2-Azido-3-O-hexadecyl-1,3-propanediol (56-4) Regioselective azidotrimethylsilylation 
(Ponpipom & Bugianesi, 1984; He et al. 1999) of 3-O-hexadecyl-sn-glycerol was carried out as 
described previously (He et al. 1999; Byun et al. 2010)  The activation of 3-O-hexadecyl-sn-
glycerol (3.17 g, 10.0 mmol) with Ph3P (3.42 g, 13.0 mmol) and diisopropyl azodicarboxylate 
(DIAD, 3.2 mL, 15 mmol) followed by reaction with trimethylsilyl azide (TMSN3, 2.2 mL, 13 
mmol) afforded crude the silyloxy azide, which was used without further purification.  After 
removal silyl protecting group with tetra-n-butylammonium fluoride (TBAF, 25 mL of a 1 M 
solution in THF containing 5% H2O) the crude product was purified by silica gel 
chromatography (elution first with 150 mL of hexanes/EtOAc 50/1 and then with 
hexanes/EtOAc 6:1) to give 2.60 g (76%) of 56-4 as a white solid:  mp 37-39 °C, 38-39 °C; 37-
39 °C; [D]25D +14.5° (c 1.0, CHCl3), [D]27D +14.1° (c 1.0, CHCl3); [D]27D +14.5° (c 1.0, 
CHCl3); 1H NMR G 0.86 (t, 3H, J = 7.0 Hz), 1.23 (m, 26H), 1.54 (m, 2H), 1.91 (br s, 1H), 3.45 
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(dt, 2H, J = 6.6, 1.5 Hz), 3.58-3.75 (m, 5H); 13C NMR G 14.10, 22.68, 25.97, 29.35, 29.41, 
29.56, 29.59, 29.65, 29.68, 31.91, 62.18, 63.09, 71.01, 71.91. 
 
 
 
(S)-2-Amino-3-O-hexadecyl-1,3-propanediol (56-5) (Gijsbers et al. 2002).  A mixture of azide 
56-4 (103 mg, 0.30 mmol) and Pd/C (10 mg) in 20 mL of methanol was stirred overnight under 
a hydrogen atmosphere.  After Pd/C was removed by passing the mixture through a pad of 
Celite, the filtrate was concentrated under reduced pressure to give 95 mg (100%) of the target 
2-amino alcohol, 56-5; 1H NMR (CDCl3) G 0.88 (t, 3H, J = 6.6 Hz), 1.25 (m, 26H), 1.56 (q, 2H, 
J = 7.0 Hz), 3.37-3.43 (m, 4H), 3.44-3.54 (m, 1H), 3.60-3.64 (m, 1H); 13C NMR G 14.1, 22.7, 
26.1, 29.3, 29.46, 29.50, 29.58, 29.61, 29.65, 29.68, 31.9, 52.1,65.0, 71.7, 73.8.  
 
 
 
(2S,3R)-4-(Tetradecyloxy)-2-amino-1,3-butanediol (77-6).  Ethyl (2S,3R)-4-tetradecyloxy-2-
azido-3-hydroxybutanonate was prepared by asymmetric dihydroxylation (He et al. 2000) and 
converted to (2S,3R)-4-(tetradecyloxy)-2-azido-1,3-butanediol (77-5) as described previously 
(Byun et al. 2013). The azido group was reduced by hydrogenation with Pd/C in methanol, 
giving 77-6; 1H NMR (CDCl3) G 0.88 (t, J = 6.7 Hz, 3H), 1.26 (s, 22H), 1.54-1.61 (m, 2H), 
2.48 (br s, 3H), 2.93 (br s, 1H), 3.42-3.52 (m, 4H), 3.56 (dd, J = 4.5, 9.7 Hz, 1H), 3.61-3.69 (m, 
2H), 3.70-3.76 (m, 1H); 13C NMR (CDCl3) G 14.1, 22.7, 26.1, 29.3, 29.44, 29.49, 29.56, 29.59, 
29.6, 29.6, 31.9, 54.3, 64.4, 71.8, 72.0, 72.5. 
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Ethyl (2S,3R)-2-(O-Phthalimido-oxy)-3-hydroxyoctadecanoate (67-621).  To a solution of 
ethyl (2S,3R)-2,3-dihydroxyoctadecanoate (Byun et al. 2013) (345 mg, 1.0 mmol) in 30 mL of 
dry CH2Cl2 was added 240 PL (3.0 mmol) of pyridine at room temperature.  After the mixture 
was stirred and chilled to 0 °C, 110 PL (3.0 mmol) of SOCl2 was added slowly.  The reaction 
mixture was stirred for 30 min, and then was filtered through a pad of silica gel in a sintered 
glass funnel.  After the pad was washed with 100 mL of hexane/EtOAc (4:1), the filtrate was 
concentrated and further dried on a vacuum pump (1 h).  The crude sulfite intermediate was 
used in the subsequent oxidation without further purification.  To a solution of the crude cyclic 
sulfite in 20 mL of MeCN was added 321 mg (1.5 mmol) of NaIO4.  The heterogeneous 
mixture was stirred vigorously while 4 mg (0.010 mmol) of RuCl3 3H2O in 4 mL of H2O was 
added quickly.  The reaction mixture was stirred at room temperature about 30 min.  On 
addition of Et2O (60 mL) to quench the reaction, the reaction mixture separated into two layers.  
After the top light brown clear solution was separated from the bottom slurry, a minimum 
volume of H2O was added to dissolve the slurry.  The aqueous phase was extracted with Et2O 
(2 x 60 mL).  The organic phases were combined, dried (Na2SO4), and passed through a small 
pad of silica gel in order to remove the black color.  Concentration of the filtrate followed by 
drying under vacuum gave the crude cyclic sulfate.  To a solution of N-hydroxyphthalimide 
(213 mg, 1.30 mmol) and Et3N (132 mg, 1.30 mmol) in 30 mL of MeCN was added a solution 
of crude cyclic sulfate in 10 mL of MeCN.  The reaction mixture was stirred overnight at room 
temperature.  Most of the acetonitrile was removed on a rotary evaporator, and the residue was 
dried by high vacuum (0.8 Torr).  Then Et2O (100 mL) and 20% aqueous H2SO4 (50 mL) were 
added, and the heterogeneous mixture was stirred vigorously at room temperature until the 
hydrolysis was completed.  The layers were separated, and the aqueous layer was extracted 
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with Et2O (2 X 100 mL).  Anhydrous K2CO3 (100 mg) was added to the combined organic 
phase to remove the dissolved H2SO4.  The ether solution was dried (Na2SO4), filtered through 
a small pad of silica gel in a sintered glass funnel, and concentrated to give a residue.  The 
product was purified by column chromatography on silica gel (elution with hexane/EtOAc 2:1) 
to give 374 mg (76%) of 67-621; 1H NMR (CDCl3) G 0.88 (t, 3H, J = 6.6 Hz), 1.26 (m, 26H), 
1.33 (t, 3H, J = 7.2 Hz), 3.39 (br s, 1H), 4.05(dt, 1H, J = 3.5, 8.9 Hz), 4.25-4.38 (m, 2H), 4.65 
(d, 1H, J = 3.5 Hz), 7.79 (dd, 2H, J = 3.1, 5.5 Hz), 7.86 (dd, 2H, J = 3.1, 5.5 Hz); 13C NMR 
(CDCl3) G 14.1, 22.7, 25.9, 29.3, 29.44, 29.48, 29.54, 29.63, 29.65, 29.67, 31.8, 31.9, 61.8, 
70.6, 88.7, 123.9, 128.6, 134.9, 163.7, 166.9; HRMS (M + Na) +, calculated for C28H43NNaO6 
512.2983, found 512.2983.  
 
 
(2S,3R)-2-O-(tert-Butoxycarbonylamido-oxy)-octadecane-1,3-diol (67-623).  To a solution 
of 184 mg (0.375 mmol) of 67-621 in 50 mL of THF was added 52 mg (1.34 mmol) of NaBH4, 
followed by 50 PL of MeOH at 0 °C.  The reaction mixture was stirred vigorously and allowed 
to warm to room temperature.  To the reaction mixture were added 1 mL of aqueous 1 M HCl 
solution and 100 mL of MeOH.  The solvents were removed to give a residue.  To the residue 
were added 1.1 g (1.51 mmol) of Boc2O (ca. 30% in toluene solution), 20 mL of CH2Cl2, and 5 
mL of aqueous 1 M NaOH solution.  After 24 h, the mixture was diluted with 100 mL of 
CH2Cl2, and washed with brine and water.  The organic layer was dried (Na2SO4) and 
concentrated.  The product was purified by column chromatography on silica gel (elution with 
hexane/EtOAc 1:1) to give 85 mg (51%) of 67-623; 1H NMR (CDCl3) G 0.88 (t, 3H, J = 6.6 
Hz), 1.49 (s, 9H), 1.46-1.54 (m, 2H), 1.77 (br s, 1H), 3.60-3.67 (m, 2H), 3.77-3.94 (m, 3H), 
7.50 (s, 1H); 13C NMR (CDCl3) G 14.1, 22.7, 26.1, 28.1, 29.4, 29.57, 29.62, 29.66, 29.7, 31.9, 
32.8, 59.9, 70.2, 83.0, 88.9, 158.9; HRMS (M + Na) +, calculated for C23H47NNaO5+ 440.3346, 
found 440.3343. 
 
16 
 
 
(2S,3R)-2-O-(Aminooxy)-octadecane-1,3-diol Hydrobromide Salt (67-622).  To a solution of 
67-623 (76 mg, 0.18 mmol) in 5 mL of CH2Cl2 was added 150 PL (1.1 mmol) of TMSBr at -78 
°C.  The mixture had been stirred for 3 h at -78 °C, and then was kept at -20 °C overnight.  
After the solvents were removed, the residue was dissolved in 10 mL of 95% MeOH with 
stirring for 1 h.  Removal of the solvent afforded 73 mg (100%) of 67-622 (hydrobromide salt); 
1H NMR (CDCl3/CD3OD) G 0.89 (t, 3H, J = 6.6 Hz), 1.27 (m, 26H), 1.41-1.74 (m, 2H), 3.61-
4.22(m, 4H); 13C NMR (CDCl3/CD3OD) G 13.81, 22.4, 25.5, 29.1, 29.29, 29.36, 29.40, 29.45, 
31.6, 61.0, 70.4, 87.6; HRMS (M + H) +, calculated for C18H40NO3+ 318.3003, found 318.3005.  
The free amine was found to be unstable. 
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Figure legends  
 
Figure 1. Chemical Structures 
Figure 2. 77-6, but not 56-5 enhances IL-ȕUHOHDVHin the presence and absence 
of LPS in differentiated U937 cells.  Differentiated U937 cells were treated with 56-5 (10 
µM) or 77-6 (10 µM) for 1 hour (a) or stimulated with LPS (1 µg/ml) for 2 hours and then 
treated with 56-5 (10 µM) or 77-6 (10 µM) for 1 hour (b), and the supernatants assayed for 
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IL-ȕE\(/,6$'DWDVKRZQDUHWKHPHDQ6(0RIDWOHDVWH[SHULPHQWV6WXGHQW¶V7-test 
was carried out. ***p<0.001. 
Figure 3. Sphingosine enhances IL-ȕ UHOHDVH in the presence of LPS in 
differentiated U937 cells. Differentiated U937 cells were stimulated with LPS (1 µg/ml) for 
2 hours prior to treatment with sphingosine (Sph, 20 µM) for 1 hour. The supernatants were 
collected and assayed for IL-ȕE\(/,6$'DWD VKRZQDUH WKHPHDQ 6(0RI DW OHDVW 
experiments. Student’s T-test was carried out.  ***p<0.001. 
Figure 4. S1P, C2 ceramide and ROMe do not affect IL-ȕUHOHDVHDifferentiated 
U937 cells were stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with 
erythroS1P (1 and 10 µM), C2 ceramide (10 and 50 µM) or ROMe (10 µM) for 1 hour. The 
supernatants were collected and assayed for IL-ȕE\(/,6$  Data shown are the mean ± 
SEM of at least 3 experiments. Student’s T-test was carried out. ***p<0.001. 
Figure 5. The Caspase-1 inhibitor Ac-YVAD-CHO prevents the enhancement of 
LPS-stimulated IL-ȕ release by 77-6 and sphingosine. Differentiated U937 cells were 
treated with vehicle (grey bars) or Ac-YVAD-CHO (10 µM) for 15 min (black bars), 
stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with 56-5 or 77-6 (both at 10 
PM) or 20 µM Sph for 1 hour.  Data shown are the mean ± SEM of at least 3 experiments. 
Student’s T-test was carried out.  *p<0.05, **p<0.01, ns not significant. 
Figure 6. The Cathepsin B inhibitor CA-074Me prevents the enhancement of 
LPS-stimulated IL-ȕUHOHDVHE\VSKLQJRVLQHEXWQRW-6. Differentiated U937 cells were 
treated with vehicle (grey bars) or CA-074Me (10 µM, black bars) for 15 min, stimulated 
with LPS (1 µg/ml) for 2 hours prior to treatment with 56-5 or 77-6 (both at 10 µM) or Sph 
(20 µM) for 1 hour. Data shown are the mean ± SEM of at least 3 experiments. Student’s T-
test was carried out. *p<0.05, **p<0.01, ns not significant. 
Figure 7. PP2A inhibitor okadaic acid does not affect IL-ȕUHOHDVHDifferentiated 
U937 cells were stimulated with LPS (1 µg/ml) for 2 hours, treated with vehicle (grey bars) 
or okadaic acid (0.5 µM) for 15 min (black bars), prior to treatment with 56-5 or 77-6 (both at 
10 PM) or 20 µM Sph for 1 hour. Data shown are the mean ± SEM of at least 3 experiments. 
Student’s T-test was carried out. *p<0.05, **p<0.01, ***p<0.001, ns not significant. 
Figure 8. Forskolin inhibits the enhancement of LPS-stimulated IL-ȕUHOHDVH by 
sphingosine but not 77-6. Differentiated U937 cells were treated with vehicle (grey bars) or 
Forskolin (10 µM) for 30 min (black bars), stimulated with LPS (1 µg/ml) for 2 hours prior to 
treatment with 56-5 or 77-6 (both at 10 PM) or 20 µM Sph for 1 hour. Data shown are the 
mean ± SEM of at least 3 experiments. Student’s T-test was carried out. *p<0.05, **p<0.01, 
ns not significant. 
Figure 9. The effect of 56-5, 77-6 or FTY720 on disease progression in EAE.  
EAE-treated mice were dosed with FTY720 (0.4 mg/kg) or 56-5 (2mg/kg) or 77-6 (8 mg/kg).  
(A) Clinical scores are plotted against time and are represented as means +/- SEM for n=6 
mice/treatment. (B) Immunohistochemical of spinal section with specific anti-CD4 or anti-
CD11b or anti-F4/80 antibodies.  Spinal sections from naïve mice are also shown stained with 
anti-CD4 or anti-CD11b or anti-F4/80 antibodies. Results are representative for n=6 
animals/treatment group.  Arrows denote infiltration of inflammatory cells. 
Figure 10.  The effect 56-5, 77-6 or FTY720 on myc-tagged S1P1 expression in 
CCL39 cells.  CCL39 cells stably over-expressing myc-tagged S1P1 were treated with 56.5 
(10 PM) or 77-6 (10 PM) or FTY720 (100 nM) for 24 h.  Cell lysates were then western 
blotted with anti-myc antibodies.  Results are representative of 3 independent experiments. 
 
ABBREVIATIONS 
DAMPs, Danger associated molecular patterns; DMEM, Dulbeccos Modified Eagles Medium; 
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EAE, experimental autoimmune encephalomyelitis; ERK, extracellular signal regulated kinase; 
LPS, lipopolysaccharide; NLRP3, NOD-like receptor family, pyrin domain containing 3; IFNJ, 
interferon gamma; IL-1E, interleukin-1beta; PAF, platelet activating factor; PAMPs, Pathogen-
associated molecular patterns; PP2A, protein phosphatase 2A; PP1, protein phosphatase 1; SK, 
sphingosine kinase; S1P, sphingosine 1-phosphate; S1P1, sphingosine 1-phosphate receptor-1; 
TH, T helper cells; TLR, Toll-like receptors. 
With sphingosine 
  SK1    SK2 
Control  100  +/- 3.7   100    +/- 10 
56-2  83.3 +/- 1.5   133.5 +/- 9.6 
56-3  90.9 +/- 5.4   104.7 +/- 4 
56-4  88.1 +/- 2.4   54.2   +/- 3.7 
56-5  98.6 +/- 2.7   327.9 +/- 19.2 
77-5  89.7 +/- 4.8   132.9 +/- 4.4 
77-6  128  +/- 9.7   847.5 +/- 59.3 
67-622  14.1 +/- 1.2   105    +/- 7.5 
 
Without sphingosine 
  SK1    SK2 
56-4    9.4   +/- 1.6   11      +/- 1.1 
56-5  42.4 +/- 0.3   251.8 +/- 14.9 
77-5   8.1   +/- 8.5   23.9   +/- 1.4 
77-6  88.2 +/- 2.7   822.6 +/- 50.2 
67-622  0.8   +/- 1.2   21.9   +/- 1.3 
 
Table 1 
SK1 and SK2 activity was measured according to the Methods.  Compounds were tested in 
combination with sphingosine (control activity in assay with sphingosine alone =100%) or in  
the absence of sphingosine (activity in absence of compounds = 0%). 
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